Truist Financial analyst Joon Lee assigned a Buy rating to the stock today. The company’s shares closed last Friday at $42.02.Don't Miss Our ...
4. Verona’s Ohtuvayre (ensifentrine) for COPD Just as Verona Pharma secured the FDA nod to market inhalable COPD drug Ohtuvayre in June, its commercial prospects seemed to improve markedly. While ...
Verona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics to treat respiratory diseases. The company's product candidate is RPL554, an inhaled dual ...
Verona Pharma has agreed a new $400 million debt facility with Oxford Finance and Hercules Capital designed to help the company navigate the possible approval and launch of ensifentrine ...
Verona Pharma is a clinical stage, pre-revenue, biopharmaceutical company that focuses on the development and commercialization of therapies for the treatment of respiratory diseases with unmet ...
LONDON and RALEIGH, N.C., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the ...
Verona Pharma recently got approval for ensifentrine in COPD. Ensifentrine has a differentiated MoA and superior safety profile. Despite a diverse market, Verona will find its own place here.
European equities traded in the US as American depositary receipts were up slightly late Tuesday morning, rising 0.14% to 1,296.03 on the S&P Europe Select ADR Index. From continental Europe, the ...
Centiva Capital LP lowered its stake in shares of Verona Pharma plc (NASDAQ:VRNA – Free Report) by 37.4% in the third quarter ...
While not every stock... Verona Pharma (VRNA) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently ...
On Oct. 22, Caligan announced that it has taken a position in Verona Pharma. Verona Pharma is a clinical stage, pre-revenue, biopharmaceutical company that focuses on the development and ...
Verona Pharma is a biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of chronic respiratory diseases with significant unmet medical needs.